In this episode of The Good GP, Dr Sean Stevens welcomes Dr Paul Effler, Medical Coordinator of the Communicable Disease Control Directorate in WA, to discuss the new RSV immunisation, Nirsevimab. They explore the differences between traditional vaccines and Nirsevimab, its effectiveness, safety, target group, and the likelihood of a national rollout. They also dive into the seasonal patterns of RSV and the co-administration of Nirsevimab with other vaccines. Providing valuable insights into the development and potential impact of this new immunisation. The Good GP Podcast is a proud member of the Talking HealthTech Podcast Network - the premier audio destination for cutting-edge insights and thought leadership in healthcare delivery, innovation, digital health, healthcare ICT, and commercialization. Learn more at www.talkinghealthtech.com/podcast/network If you have any questions or would like to contact The Good GP, send an email to [email protected] Mentioned in this episode: Proudly supported by Medtech Global: The Good GP Podcast is sponsored by Medtech Global, they help GPs be GPs by working with clinicians in Australia and New Zealand to develop Patient Management Systems and healthcare technology. Visit the link for more information: Medtech Global